Do analysts rate ADMA or PBYI?

ADMA Biologics currently has a consensus target price of $19.67, indicating a potential upside of 139.55%. Given ADMA Biologics' stronger consensus rating and higher probable upside, equities analysts plainly believe ADMA Biologics is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer ADMA or PBYI?

In the previous week, ADMA Biologics had 28 more articles in the media than Puma Biotechnology. MarketBeat recorded 30 mentions for ADMA Biologics and 2 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.96 beat ADMA Biologics' score of 0.24 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 3 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PBYI or CTMX?

CytomX Therapeutics has a consensus price target of $12.10, indicating a potential upside of 301.99%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 CytomX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91

Does the media refer more to PBYI or CTMX?

In the previous week, CytomX Therapeutics had 2 more articles in the media than Puma Biotechnology. MarketBeat recorded 4 mentions for CytomX Therapeutics and 2 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.96 beat CytomX Therapeutics' score of 0.91 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer PBYI or TRDA?

Entrada Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 170.90%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Entrada Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media prefer PBYI or TRDA?

In the previous week, Entrada Therapeutics had 3 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for Entrada Therapeutics and 2 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.96 beat Entrada Therapeutics' score of 0.27 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Entrada Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate PBYI or AVBP?

ArriVent BioPharma has a consensus price target of $43.38, suggesting a potential upside of 42.03%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe ArriVent BioPharma is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 ArriVent BioPharma 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82

Does the media favor PBYI or AVBP?

In the previous week, Puma Biotechnology and Puma Biotechnology both had 2 articles in the media. Puma Biotechnology's average media sentiment score of 0.96 beat ArriVent BioPharma's score of 0.94 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ArriVent BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PBYI or SEPN?

Septerna has a consensus target price of $45.78, suggesting a potential upside of 27.34%. Given Septerna's stronger consensus rating and higher probable upside, analysts plainly believe Septerna is more favorable than Puma Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Septerna 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91

Which has stronger valuation & earnings, PBYI or SEPN?

Puma Biotechnology has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Puma Biotechnology $228.40M 1.63 $31.11M $0.48 15.27 Septerna $45.95M 35.27 -$48.88M -$0.81 N/A

Does the media favor PBYI or SEPN?

In the previous week, Septerna had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 3 mentions for Septerna and 2 mentions for Puma Biotechnology. Septerna's average media sentiment score of 0.97 beat Puma Biotechnology's score of 0.96 indicating that Septerna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Puma Biotechnology (PBYI) Competitors

$7.33 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$7.32 0.00 (-0.07%)

As of 06/12/2026 06:42 PM Eastern

Compare

PBYI vs. ADMA, CTMX, TRDA, AVBP, and SEPN

Should you buy Puma Biotechnology stock or one of its competitors? MarketBeat compares Puma Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Puma Biotechnology include ADMA Biologics (ADMA), CytomX Therapeutics (CTMX), Entrada Therapeutics (TRDA), ArriVent BioPharma (AVBP), and Septerna (SEPN). These companies are all part of the "pharmaceutical products" industry.

How does Puma Biotechnology compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

ADMA Biologics has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Puma Biotechnology has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by company insiders. Comparatively, 22.2% of Puma Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ADMA Biologics has higher revenue and earnings than Puma Biotechnology. ADMA Biologics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	3.73	$146.93M	$0.68	12.07
Puma Biotechnology	$228.40M	1.63	$31.11M	$0.48	15.27

ADMA Biologics has a net margin of 32.43% compared to Puma Biotechnology's net margin of 10.69%. ADMA Biologics' return on equity of 39.98% beat Puma Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Puma Biotechnology	10.69%	20.30%	12.05%

ADMA Biologics currently has a consensus target price of $19.67, indicating a potential upside of 139.55%. Given ADMA Biologics' stronger consensus rating and higher probable upside, equities analysts plainly believe ADMA Biologics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, ADMA Biologics had 28 more articles in the media than Puma Biotechnology. MarketBeat recorded 30 mentions for ADMA Biologics and 2 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.96 beat ADMA Biologics' score of 0.24 indicating that Puma Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	3 Very Positive mention(s)	1 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ADMA Biologics beats Puma Biotechnology on 12 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to CytomX Therapeutics?

Puma Biotechnology (NASDAQ:PBYI) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

CytomX Therapeutics has a consensus price target of $12.10, indicating a potential upside of 301.99%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Puma Biotechnology has a net margin of 10.69% compared to CytomX Therapeutics' net margin of -166.40%. Puma Biotechnology's return on equity of 20.30% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

Puma Biotechnology has higher revenue and earnings than CytomX Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.63	$31.11M	$0.48	15.27
CytomX Therapeutics	$76.20M	6.72	-$17.37M	-$0.41	N/A

Puma Biotechnology has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market.

In the previous week, CytomX Therapeutics had 2 more articles in the media than Puma Biotechnology. MarketBeat recorded 4 mentions for CytomX Therapeutics and 2 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.96 beat CytomX Therapeutics' score of 0.91 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 3.8% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Puma Biotechnology beats CytomX Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Puma Biotechnology compare to Entrada Therapeutics?

Puma Biotechnology (NASDAQ:PBYI) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

In the previous week, Entrada Therapeutics had 3 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for Entrada Therapeutics and 2 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 0.96 beat Entrada Therapeutics' score of 0.27 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Entrada Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Entrada Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 170.90%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Puma Biotechnology has higher revenue and earnings than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.63	$31.11M	$0.48	15.27
Entrada Therapeutics	$25.42M	9.87	-$143.75M	-$3.99	N/A

Puma Biotechnology has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

Puma Biotechnology has a net margin of 10.69% compared to Entrada Therapeutics' net margin of -2,895.05%. Puma Biotechnology's return on equity of 20.30% beat Entrada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

Summary

Puma Biotechnology beats Entrada Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Puma Biotechnology compare to ArriVent BioPharma?

Puma Biotechnology (NASDAQ:PBYI) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

ArriVent BioPharma has a consensus price target of $43.38, suggesting a potential upside of 42.03%. Given ArriVent BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe ArriVent BioPharma is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Puma Biotechnology has a net margin of 10.69% compared to ArriVent BioPharma's net margin of 0.00%. Puma Biotechnology's return on equity of 20.30% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Puma Biotechnology has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

In the previous week, Puma Biotechnology and Puma Biotechnology both had 2 articles in the media. Puma Biotechnology's average media sentiment score of 0.96 beat ArriVent BioPharma's score of 0.94 indicating that Puma Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ArriVent BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Puma Biotechnology has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.63	$31.11M	$0.48	15.27
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Summary

Puma Biotechnology beats ArriVent BioPharma on 10 of the 15 factors compared between the two stocks.

How does Puma Biotechnology compare to Septerna?

Puma Biotechnology (NASDAQ:PBYI) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

61.3% of Puma Biotechnology shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by company insiders. Comparatively, 5.8% of Septerna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Septerna had 1 more articles in the media than Puma Biotechnology. MarketBeat recorded 3 mentions for Septerna and 2 mentions for Puma Biotechnology. Septerna's average media sentiment score of 0.97 beat Puma Biotechnology's score of 0.96 indicating that Septerna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Puma Biotechnology has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market. Comparatively, Septerna has a beta of 2.39, suggesting that its stock price is 139% more volatile than the broader market.

Septerna has a consensus target price of $45.78, suggesting a potential upside of 27.34%. Given Septerna's stronger consensus rating and higher probable upside, analysts plainly believe Septerna is more favorable than Puma Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Puma Biotechnology has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.63	$31.11M	$0.48	15.27
Septerna	$45.95M	35.27	-$48.88M	-$0.81	N/A

Puma Biotechnology has a net margin of 10.69% compared to Septerna's net margin of -49.88%. Puma Biotechnology's return on equity of 20.30% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
Septerna	-49.88%	-12.72%	-8.87%

Summary

Puma Biotechnology beats Septerna on 9 of the 17 factors compared between the two stocks.

Get Puma Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBYI vs. The Competition

Export

Metric	Puma Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$373.10M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	15.27	20.00	24.00	24.42
Price / Sales	1.63	306.82	514.36	111.24
Price / Cash	8.79	53.61	27.48	37.92
Price / Book	2.83	8.32	10.54	6.82
Net Income	$31.11M	$23.94M	$3.57B	$337.56M
7 Day Performance	7.01%	1.84%	0.60%	1.17%
1 Month Performance	5.92%	-0.04%	1.56%	3.16%
1 Year Performance	118.81%	44.82%	25.42%	30.58%

Puma Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBYI Puma Biotechnology	1.1496 of 5 stars	$7.33 flat	N/A	+118.8%	$373.10M	$228.40M	15.27	200	Short Interest Increase
ADMA ADMA Biologics	4.5062 of 5 stars	$8.20 +1.7%	$19.00 +131.8%	-60.5%	$1.90B	$510.17M	12.08	530	Trending News
CTMX CytomX Therapeutics	3.5794 of 5 stars	$2.97 +0.9%	$12.10 +308.1%	+9.5%	$505.98M	$76.20M	N/A	170
TRDA Entrada Therapeutics	3.7258 of 5 stars	$6.40 +2.2%	$17.50 +173.5%	-14.9%	$248.88M	$5.74M	N/A	110	Gap Up
AVBP ArriVent BioPharma	2.2738 of 5 stars	$30.25 -0.8%	$43.38 +43.4%	+31.2%	$1.41B	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBYI) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, AVBP, and SEPN

How does Puma Biotechnology compare to ADMA Biologics?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Summary

How does Puma Biotechnology compare to ArriVent BioPharma?

Summary

How does Puma Biotechnology compare to Septerna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Puma Biotechnology (PBYI) Competitors

PBYI vs. ADMA, CTMX, TRDA, AVBP, and SEPN

How does Puma Biotechnology compare to ADMA Biologics?

Which has more risk & volatility, ADMA or PBYI?

Do insiders & institutionals have more ownership in ADMA or PBYI?

Which has better valuation & earnings, ADMA or PBYI?

Is ADMA or PBYI more profitable?

Do analysts rate ADMA or PBYI?

Does the media prefer ADMA or PBYI?

Summary

How does Puma Biotechnology compare to CytomX Therapeutics?

Do analysts rate PBYI or CTMX?

Is PBYI or CTMX more profitable?

Which has stronger valuation & earnings, PBYI or CTMX?

Which has more volatility & risk, PBYI or CTMX?

Does the media refer more to PBYI or CTMX?

Do insiders and institutionals believe in PBYI or CTMX?

Summary

How does Puma Biotechnology compare to Entrada Therapeutics?

Does the media prefer PBYI or TRDA?

Do analysts prefer PBYI or TRDA?

Do institutionals and insiders hold more shares of PBYI or TRDA?

Which has higher valuation and earnings, PBYI or TRDA?

Which has more volatility & risk, PBYI or TRDA?

Is PBYI or TRDA more profitable?

Summary

How does Puma Biotechnology compare to ArriVent BioPharma?

Do analysts rate PBYI or AVBP?

Is PBYI or AVBP more profitable?

Which has more volatility and risk, PBYI or AVBP?

Does the media favor PBYI or AVBP?

Do insiders and institutionals hold more shares of PBYI or AVBP?

Which has preferable earnings & valuation, PBYI or AVBP?

Summary

How does Puma Biotechnology compare to Septerna?

Do insiders & institutionals hold more shares of PBYI or SEPN?

Does the media favor PBYI or SEPN?

Which has more risk & volatility, PBYI or SEPN?

Do analysts rate PBYI or SEPN?

Which has stronger valuation & earnings, PBYI or SEPN?

Is PBYI or SEPN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBYI vs. The Competition

Puma Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools